logo-loader
viewReNeuron Group PLC

ReNeuron CFO 'pleased' with reformulation of degenerative diseases treatment

Michael Hunt, chief financial officer for the stem cell specialist ReNeuron Group Plc (LON:RENE) updates Proactive on two of their clinical programmes.

Hunt says they're preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke.

He also mentions that a new formulation of their human retinal progenitor cell which is being trialled to treat degenerative diseases of the retina, represents a major step forward for them.

Quick facts: ReNeuron Group PLC

Price: 135 GBX

LSE:RENE
Market: LSE
Market Cap: £42.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron's Michael Hunt talks new potential for its CTX therapy in treating...

ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott following the release of new positive data relating to its CTX cell therapy candidate which has been published in the peer-reviewed scientific journal Stem Cells. He says the new data shows for the first...

2 weeks, 6 days ago

2 min read